IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - ...

Alliance News 10 July, 2023 | 7:53AM
Email Form Facebook Twitter LinkedIn RSS

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Current stock price: 193.00 pence

12-month change: down 22%

By Sabrina Penty, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
HUTCHMED (China) Ltd 350.00 GBX -0.57 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures